A3373
Based on 1 Customer Validation
A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis.
For research use only. We do not sell to patients.
- Purity: 99.57%
- CAS No.: 2324948-66-3
- Formula: C17H9F7N2O
- Molecular Weight:390.25
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Phospholipase Isoforms
More
Biological Activity
|
PLD1 325 nM (IC50) |
PLD2 15.15 μM (IC50) |
Chemical Information
-
CAS No. 2324948-66-3
-
Appearance Solid
-
Molecular Weight 390.25
-
Formula C17H9F7N2O
-
Color White to off-white
-
SMILES
O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC3=C(N2)C=CC(F)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (256.25 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Won Chan Hwang, et al. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.Exp Mol Med. 2022 Sep;54(9):1563-1576. [Content Brief]
[2]. Jin-Sil Park, et al. A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation. Immunol Lett. 2023 Sep 16:263:87-96. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5625 mL | 12.8123 mL | 25.6246 mL | 64.0615 mL |
| 5 mM | 0.5125 mL | 2.5625 mL | 5.1249 mL | 12.8123 mL | |
| 10 mM | 0.2562 mL | 1.2812 mL | 2.5625 mL | 6.4061 mL | |
| 15 mM | 0.1708 mL | 0.8542 mL | 1.7083 mL | 4.2708 mL | |
| 20 mM | 0.1281 mL | 0.6406 mL | 1.2812 mL | 3.2031 mL | |
| 25 mM | 0.1025 mL | 0.5125 mL | 1.0250 mL | 2.5625 mL | |
| 30 mM | 0.0854 mL | 0.4271 mL | 0.8542 mL | 2.1354 mL | |
| 40 mM | 0.0641 mL | 0.3203 mL | 0.6406 mL | 1.6015 mL | |
| 50 mM | 0.0512 mL | 0.2562 mL | 0.5125 mL | 1.2812 mL | |
| 60 mM | 0.0427 mL | 0.2135 mL | 0.4271 mL | 1.0677 mL | |
| 80 mM | 0.0320 mL | 0.1602 mL | 0.3203 mL | 0.8008 mL | |
| 100 mM | 0.0256 mL | 0.1281 mL | 0.2562 mL | 0.6406 mL |